Sulfonyl acetamides as nlrp3 inhibitors

Abstract

The present invention relates to compounds of formula (I) wherein Q is selected from O or S; Ris a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; Ris a cyclic group substituted at the a and a' positions, wherein the substituent at the α-position is a monovalent heterocyclic group or a monovalent aromatic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the cyclic group may optionally be further substituted; Rand Rare each independently hydrogen, halogen, —OH, —NH, —CN, —R, —OR, —NHRor —N(R); or Rand Rtogether with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and Ris independently optionally substituted C-Calkyl. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.